![]() |
市場調查報告書
商品編碼
1439268
定量吸入器 - 全球市場回顧、競爭格局、市場預測 (2030)Metered Dose Inhaler Devices - Market Insights, Competitive Landscape, and Market Forecast - 2030 |
2023年全球計量吸入器市場規模預計為166.13億美元,到2030年將達到214.23億美元,2024-2030年預測期間複合年增長率為3.99%,預計將增長。 該市場受到COVID-19患病率上升、糖尿病患病率上升、哮喘患病率上升、囊性纖維化病例激增以及慢性阻塞性肺病(COPD)患病率的推動。正增長歸因於多種因素,例如消費者數量的快速增加、人口老化的增加以及產品技術進步的增加。 因此,計量吸入器市場預計在 2024-2030 年預測期內將成長。
定量吸入器的市場動態
糖尿病盛行率的增加是定量吸入器市場的主要驅動因素之一。 例如,根據國際糖尿病聯盟(IDF)2023年發布的IDF糖尿病圖譜第十版,全球20歲至79歲之間約有5.37億人患有糖尿病。 此外,預計到 2030 年,糖尿病將影響全球 6.43 億人,到 2045 年,糖尿病將影響 7.83 億人。 此外,透過定量吸入器施用胰島素粉末來治療糖尿病。 因此,糖尿病患者數量的增加將增加對計量吸入器的需求,從而在預測期(2024-2030年)推動全球計量吸入器市場的成長。
此外,推動計量吸入器市場成長的另一個主要因素是氣喘盛行率的增加。 例如,根據世界衛生組織(WHO)2023年發布的數據,2019年全球估計有2.62億人患有氣喘。 此外,根據美國氣喘和過敏基金會 2023 年發布的數據,2019 年美國約有 2,500 萬人患有氣喘。 因此,定量吸入器用於治療氣喘。 因此,氣喘盛行率的上升將增加對計量吸入器的需求,推動整個計量吸入器市場在預測期內(2024-2030年)向前發展。
然而,缺乏對計量吸入器的認識以及與該設備相關的嚴重副作用可能會阻礙全球計量吸入器市場的成長。
COVID-19 大流行對計量吸入器市場產生了正面影響。 這是由於COVID-19對肺部的嚴重影響,估計從COVID-19中康復的患者可能會遭受作為COVID-19後遺症的呼吸道感染,對吸入器的需求激增。 因此,在2024-2030年的預測期內,計量吸入器的需求預計將持續增加。
定量吸入器市場細分分析
在計量吸入器市場的應用領域,慢性阻塞性肺病 (COPD) 預計將在 2023 年佔據重要收入。 定量吸入器是便攜式、易於使用的設備,能夠以氣霧劑的形式將氣喘藥物輸送到肺部。 這些藥物可與多種慢性阻塞性肺病藥物一起使用,包括類固醇(包括 Flobento 氫氟烷 (HFA))、類固醇/支氣管擴張劑組合(如 symbicort)和組合藥物。 因此,與計量吸入器相關的這些優點可能會增加對計量吸入器的需求並增加整個計量吸入器市場。 另一方面,增加與計量吸入器相關的產品推出也將推動其市場成長。
2020年10月,跨國製藥公司Zydus Cadila宣佈在印度推出針對慢性阻塞性肺病(COPD)患者的長效毒蕈鹼拮抗劑(LAMA)和長效β受體激動劑。宣布推出Forglyn pMDI ,印度首款加壓計量吸入器(pMDI)與(LABA)結合。
本報告提供了全球計量吸入器市場的研究和分析,包括市場規模和預測、驅動因素和挑戰以及公司和產品概況。
Metered Dose Inhaler Devices Market By Patient Type (Adult And Pedriatric), By Application (Chronic Obstructive Pulmonary Diseases (Copd), Asthma, Covid-19, Diabetes, And Others), By Distribution Channel (Online And Offline), and by geography is expected to grow at a steady CAGR forecast till 2030 owing to increasing prevalence of chronic obstructive pulmonary diseases (copd) and rising prevalence in asthma
The global metered dose inhaler devices market was valued at USD 16,613 million in 2023, growing at a CAGR of 3.99% during the forecast period from 2024 to 2030 to reach USD 21,423 million by 2030. The metered dose inhaler devices market is witnessing a positive growth owing to the various factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings. Therefore, the market for metered dose inhaler devices is estimated to grow during the forecast period from 2024 to 2030.
Metered Dose Inhaler Devices Market Dynamics:
The increased prevalence of diabetes is one of the key factors driving the market for metered dose inhaler devices. For instance, according to the International Diabetes Federation (IDF), IDF Diabetes Atlas Tenth edition released in the year 2023, worldwide, diabetes had affected about 537 million people of age between 20-79 years. Moreover, diabetes can be predicted to affect 643 million people worldwide by 2030 and 783 million people by 2045. Further, insulin powder is administered by metered dose inhalers to treat diabetes. As a result, the demand for metered dose inhaler devices rises due to an increase in diabetes cases, propelling the global metered dose inhaler devices market ahead over the forecast period (2024-2030).
Moreover, another key factor which is responsible for the growth of metered dose inhaler devices market is the increasing prevalence of asthma. For instance, according to the data published by World Health Organization (WHO) in the year 2023, in 2019, asthma afflicted an estimated 262 million individuals globally. Moreover, as per the data published by Asthma and Allergy Foundation of America in the year 2023, in 2019, approximately 25 million people had asthma in the United States. Thus, metered dose inhaler devices are used to treat asthma. Therefore, rising prevalence in asthma increases the demand for metered dose inhaler devices, which drives the overall metered dose inhaler devices market forward over the forecast period (2024-2030).
However, lack of awareness about metered dose inhaler devices and severe side effects associated with the devices, can hamper the global metered dose inhaler devices market growth.
The COVID-19 pandemic has positively impacted the market for metered dose inhaler devices, this can be due to the severe effects of COVID on lungs and it is estimated that people may have respiratory infections as an after effect of COVID, which surged the demand for metered dose inhaler devices among patients recovering with COVID, as well as shortness of breath as its prevalent symptom also contributed to the metered dose inhaler devices demand among COVID patients. Hence, the demand for metered dose inhaler devices will continue to rise in the forecast period from 2024-2030.
Metered Dose Inhaler Devices Market Segment Analysis:
Metered dose inhaler devices market by Patient Type (Adult and Pediatric), Application (Chronic Obstructive Pulmonary Diseases (COPD), Asthma, COVID-19, Diabetes, and Others), Distribution Channel (Online and Offline), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In by application segment of metered dose inhaler devices market, Chronic Obstructive Pulmonary Diseases (COPD) are expected to share a significant revenue in the year 2023. Metered dose inhaler devices are a portable, easy-to-use device that delivers asthma medicine in aerosol form to the lungs. They may be used with a variety of COPD drugs, such as steroids including flovent hydrofluoroalkane (HFA) and a combination of steroid/bronchodilators such as Symbicort, and combination medications. Thus, these benefits associated with the metered dose inhaler devices can increase the demand of metered dose inhaler devices, which could increase the metered dose inhaler devices overall market. However, a rise in product launch associated with the metered dose inhaler devices also drives its market growth.
In October 2020, Zydus Cadila, multinational pharmaceutical company, announced the launch of Forglyn pMDI, India's first pressurized Metered Dose Inhaler (pMDI) with a combination of Long Acting Muscarinic Antagonist (LAMA) and Long Acting Beta Agonist (LABA) for patients suffering from Chronic Obstructive Pulmonary Disease (COPD) in India.
Moreover, due to the interplay of all the factors mentioned above, results in the rising demand for metered dose inhaler devices, which in turn provide a conducive growth environment for overall metered dose inhaler devices during the market forecast of 2024-2030.
North America is expected to dominate the overall Metered Dose Inhaler Devices Market:
Among all the regions, North America is expected to dominate the global metered dose inhaler devices market in the year 2023 and is expected to do the same during the forecast period from 2024-2030. Factors such as the rising prevalence of asthma and surge in cystic fibrosis cases are expected to increase the demand for metered dose inhaler devices in the North American market.
According to the data published by WHO from 3 January 2020 to 21 September 2022, there have been 94,471,064 confirmed cases of COVID-19 in United States. Further, COVID-19 increases the risk of respiratory infections in the patients affecting the lungs. Thus, rising prevalence of COVID increases the demand for metered dose inhaler devices, which surges the growth for metered dose inhaler devices overall market forecast.
Moreover, as per the latest data released by American Lung Association in the year 2020, cystic fibrosis affected approximately 30,000 people in the United States. Also, as per the cystic fibrosis Canada's 2020 annual data report from the Canadian Cystic Fibrosis Registry, released that in 2020, there were 4,332 Canadians with CF, with 62% of them being adults. Further, metered dose inhalers are available for the treatment of cystic fibrosis. Therefore, surge in cystic fibrosis cases would increase the demand for metered dose inhaler devices, which boost the metered dose inhaler devices overall market growth.
Furthermore, the factors mentioned above, provide a conducive growth environment for North American region in metered dose inhaler devices market.
Metered Dose Inhaler Devices Market Key Players:
Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.
Recent Developmental Activities in the Dry Powder Inhaler Devices:
In March 2022, Novartis' Sandoz, a Swiss multinational pharmaceutical corporation, acquired, UK based delivery device development company, Coalesce Product Development Limited, developing a portfolio of inhalation devices. This includes new versions of pressurized metered dose inhalers (pMDI), breath-actuated inhalers (BAI) and pre-metered dry powder inhalers (DPI).
In February 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, announced the launch of HeroTracker® Sense, a unique digital respiratory health solution that turns a normal metered dosage inhaler (pMDI) into a smart linked healthcare device.
In September 2022, BreatheSuite Inc., a Canadian connected respiratory health startup, announced that its BreatheSuite Metered-Dose Inhaler (MDI) V1 device has acquired 510(K) approval from the US Food and Drug Administration (FDA). The BreatheSuite gadget converts conventional MDIs into smart inhalers by automatically and objectively monitoring and delivering feedback on inhaler adherence and technique for persons with asthma and COPD. It is approved for both prescription and over-the-counter usage.
Key Takeaways from the Metered Dose Inhaler Devices Market Report Study
Target Audience who can be benefited from this Metered Dose Inhaler Devices Market Report Study
Frequently Asked Questions for Metered Dose Inhaler Devices:
The Metered Dose Inhaler device (MDI) is a medication canister that is pressurised and held in a plastic container with a mouthpiece. When sprayed, it delivers a constant and predictable amount of medicine. It is the most widely utilized delivery method for treating asthma, COPD, and other respiratory illnesses.
The global metered dose inhaler devices market was valued at USD 16,613 million in 2023, growing at a CAGR of 3.99% during the forecast period from 2024 to 2030 to reach USD 21,423 million by 2030.
The metered dose inhaler devices market is witnessing a positive market growth owing to the factors such as increasing prevalence of COVID-19, rising prevalence of diabetes, increasing prevalence of asthma, surge in cystic fibrosis cases, surge in prevalence of Chronic Obstructive Pulmonary Diseases (COPD), rise in geriatric population and increase in technological advancements with respect to the product offerings.
Some of the key market players operating in the metered dose inhaler devices market include H&T Presspart Manufacturing Ltd, MidasCare, Beximco Pharmaceuticals Ltd, BioCare Group (M) Sdn Bhd, Intech Biopharm Corporation, AstraZeneca, Recipharm AB (publ), Maya Biotech Pvt. Ltd, BreatheSuite Inc, and among others.
North America is expected to dominate the global metered dose inhaler devices market. Factors contributing to the growth of metered dose inhaler devices market in the North America region are rising prevalence of COVID-19 and surge in cystic fibrosis cases.